FTC v Edwards: Defendants’ Response

Case Study

In a previous blog, we examined the complaint that the Federal Trade Commission (FTC) filed to prevent Edwards Lifesciences Corp. (Edwards) from merging with JenaValve Technology, Inc. The FTC primarily expressed concerns about competition, stating that the acquisition could eliminate direct competition and that the merger could result in a notable decrease in competition, potentially leading to reduced innovation, lower product quality, and an increase in prices within the market for transcatheter aortic valve replacement (TAVR) devices designed for aortic regurgitation (AR).